Compass is still being developed and is effectively in beta. Some content and features may be incomplete, change, or not work as expected.

Content is anchored to trusted sources where available, but Compass has not yet been clinically reviewed. It provides general information rather than medical advice.

Feedback helps us identify gaps, errors, usability problems and opportunities to improve Compass over time.

ALS Untangled finds no evidence that psilocybin slows ALS progression

Original source

PsilocybinALSUntangled · 7 January 2025

An ALS Untangled review found no studies testing psilocybin in ALS-relevant preclinical models and no case reports describing its effect on ALS progression. The review says psilocybin may affect mechanisms relevant to ALS, including neuroinflammation and brain glutamate levels, but this has not been demonstrated in ALS models or people with ALS.

Why this matters

People with ALS do not currently have evidence that psilocybin slows disease progression. ALS Untangled does not support using psilocybin for this purpose, citing the potential for serious side effects.

Limitations and context

This is an expert review, not a clinical trial or primary research study. The review reports that the relevant evidence is absent, so whether psilocybin could help or harm people with ALS remains unestablished.

Relevant to you?